[go: up one dir, main page]

DK3406609T3 - Bicykliske aza-forbindelser som muskariniske receptoragonister - Google Patents

Bicykliske aza-forbindelser som muskariniske receptoragonister Download PDF

Info

Publication number
DK3406609T3
DK3406609T3 DK18179258.1T DK18179258T DK3406609T3 DK 3406609 T3 DK3406609 T3 DK 3406609T3 DK 18179258 T DK18179258 T DK 18179258T DK 3406609 T3 DK3406609 T3 DK 3406609T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
muscarinic receptor
aza compounds
bicyclic aza
bicyclic
Prior art date
Application number
DK18179258.1T
Other languages
English (en)
Inventor
Giles Albert Brown
Julie Elaine Cansfield
Miles Stuart Congreve
Michael Alistair O'brien
Mark Pickworth
Mark David Rackham
Benjamin Gerald Tehan
Barry John Teobald
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52465550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3406609(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1402013.5A external-priority patent/GB201402013D0/en
Priority claimed from GBGB1416622.7A external-priority patent/GB201416622D0/en
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Application granted granted Critical
Publication of DK3406609T3 publication Critical patent/DK3406609T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
DK18179258.1T 2014-02-06 2015-02-06 Bicykliske aza-forbindelser som muskariniske receptoragonister DK3406609T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1402013.5A GB201402013D0 (en) 2014-02-06 2014-02-06 Pharmaceutical compounds
GBGB1416622.7A GB201416622D0 (en) 2014-09-19 2014-09-19 Pharmaceutical compounds
EP15703826.6A EP3102568B1 (en) 2014-02-06 2015-02-06 Bicyclic aza compounds as muscarinic m1 receptor agonists.

Publications (1)

Publication Number Publication Date
DK3406609T3 true DK3406609T3 (da) 2024-08-26

Family

ID=52465550

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15703826.6T DK3102568T3 (da) 2014-02-06 2015-02-06 Bicykliske aza-forbindelser som muskarin-m1-receptoragonister
DK18179258.1T DK3406609T3 (da) 2014-02-06 2015-02-06 Bicykliske aza-forbindelser som muskariniske receptoragonister

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15703826.6T DK3102568T3 (da) 2014-02-06 2015-02-06 Bicykliske aza-forbindelser som muskarin-m1-receptoragonister

Country Status (30)

Country Link
US (6) US9670183B2 (da)
EP (3) EP3406609B1 (da)
JP (7) JP6479029B2 (da)
KR (1) KR102352388B1 (da)
CN (2) CN109851610B (da)
AU (3) AU2015213900B2 (da)
BR (1) BR112016017979B1 (da)
CA (1) CA2938169C (da)
CL (1) CL2016001983A1 (da)
CY (1) CY1120834T1 (da)
DK (2) DK3102568T3 (da)
ES (2) ES2986327T3 (da)
FI (1) FI3406609T3 (da)
HR (2) HRP20181499T1 (da)
HU (1) HUE068301T2 (da)
IL (1) IL247117B (da)
LT (2) LT3102568T (da)
MX (2) MX393637B (da)
NZ (1) NZ723103A (da)
PH (1) PH12016501570B1 (da)
PL (2) PL3406609T3 (da)
PT (2) PT3102568T (da)
RS (2) RS65894B1 (da)
RU (1) RU2685230C2 (da)
SA (1) SA516371614B1 (da)
SG (1) SG11201606269WA (da)
SI (2) SI3102568T1 (da)
SM (1) SMT202400446T1 (da)
UA (1) UA122121C2 (da)
WO (1) WO2015118342A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072705A1 (en) 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
US9533970B2 (en) 2013-03-15 2017-01-03 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
FI3406609T3 (fi) 2014-02-06 2024-09-10 Nxera Pharma Uk Ltd Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
MX2017003624A (es) 2014-09-17 2017-07-13 Verseon Corp Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
SG11201706411YA (en) * 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201726675A (zh) 2015-12-23 2017-08-01 默沙東藥廠 M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
JP7046018B2 (ja) * 2016-07-01 2022-04-01 ファイザー・インク 神経性疾患および神経変性疾患を処置するための５，７－ジヒドロピロロピリジン誘導体
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201906838A (zh) 2017-06-21 2019-02-16 日商第一三共股份有限公司 Ｅｐ３００／ｃｒｅｂｂｐ抑制劑
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019027860A1 (en) * 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
PL3768669T3 (pl) * 2018-03-23 2023-07-03 Pfizer Inc. Pochodne azaspiro piperazyny
GB201810245D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11548865B2 (en) * 2019-10-09 2023-01-10 Novartis Ag 2-azaspiro[3.4]octane derivatives as M4 agonists
PH12022550860A1 (en) * 2019-10-09 2023-06-14 Novartis Ag 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
US11912705B2 (en) * 2020-08-20 2024-02-27 The Corporation Of Mercer University Cathinone derivatives, pharmaceutical formulations, and methods
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
TW202416955A (zh) 2022-08-04 2024-05-01 英商海普泰爾思治療公司 毒蕈鹼受體激動劑
KR20250086639A (ko) * 2022-09-16 2025-06-13 세레벨 쎄라퓨틱스, 엘엘씨 M4 활성제/조절제 및 이의 용도
WO2024151833A1 (en) * 2023-01-12 2024-07-18 Cerevel Therapeutics, Llc Spiro derivatives as m4 activators/modulators and uses thereof
WO2024158645A1 (en) * 2023-01-24 2024-08-02 Neurocrine Biosciences, Inc. Deuterated compounds
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法
WO2025030095A1 (en) 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CA2444595A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
US7820817B2 (en) * 2004-05-28 2010-10-26 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786308B2 (en) * 2005-03-28 2010-08-31 Vertex Pharmaceuticals Incorporated Muscarinic modulators
WO2007076070A2 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007221220A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
BRPI0708524A2 (pt) * 2006-03-03 2011-05-31 Novartis Ag compostos de n-formil hidroxilamina
GB0706188D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
MX2011004340A (es) 2008-10-29 2011-05-23 Gruenenthal Gmbh Espiroaminas sustituidas.
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
TW201211028A (en) * 2010-08-10 2012-03-16 Dainippon Sumitomo Pharma Co Fused ring pyrrolidine derivatives
WO2013072705A1 (en) * 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
JP6204476B2 (ja) * 2012-09-18 2017-09-27 ヘプタレス セラピューティックス リミテッド ムスカリンｍ１受容体作動薬としての二環式アザ化合物
SG11201508203TA (en) 2013-04-30 2015-11-27 Glaxosmithkline Ip No 2 Ltd Enhancer of zeste homolog 2 inhibitors
CA2945693C (en) 2014-02-06 2020-06-16 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
FI3406609T3 (fi) * 2014-02-06 2024-09-10 Nxera Pharma Uk Ltd Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
JP6678656B2 (ja) 2014-09-19 2020-04-08 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
CN107001331A (zh) 2014-09-19 2017-08-01 拜耳制药股份公司 作为bub1抑制剂的苄基取代的吲唑
FI3733662T3 (fi) 2014-09-19 2023-08-09 Forma Therapeutics Inc Pyridin-2(1h)-oni-kinolinonijohdannaisia mutantti-isositraattidehydrogenaasin estäjinä

Also Published As

Publication number Publication date
US9670183B2 (en) 2017-06-06
JP7652833B2 (ja) 2025-03-27
JP6479029B2 (ja) 2019-03-06
PL3102568T3 (pl) 2019-01-31
BR112016017979A2 (da) 2017-08-08
CA2938169A1 (en) 2015-08-13
US20190112294A1 (en) 2019-04-18
PL3406609T3 (pl) 2024-11-25
SA516371614B1 (ar) 2019-10-30
AU2015213900B2 (en) 2018-12-13
HUE068301T2 (hu) 2024-12-28
JP2025085736A (ja) 2025-06-05
WO2015118342A1 (en) 2015-08-13
EP3406609B1 (en) 2024-06-26
AU2020277225A1 (en) 2020-12-24
DK3102568T3 (da) 2018-10-08
JP2023073504A (ja) 2023-05-25
AU2015213900A1 (en) 2016-08-11
JP7652829B2 (ja) 2025-03-27
JP2019077725A (ja) 2019-05-23
CL2016001983A1 (es) 2017-06-23
MX371529B (es) 2020-01-31
US20200325118A1 (en) 2020-10-15
US10961225B2 (en) 2021-03-30
EP4413985A2 (en) 2024-08-14
KR102352388B1 (ko) 2022-01-17
MX2020001236A (es) 2022-06-30
HRP20181499T1 (hr) 2018-11-30
JP2023087045A (ja) 2023-06-22
ES2986327T3 (es) 2024-11-11
WO2015118342A8 (en) 2016-06-30
US20180179184A1 (en) 2018-06-28
MX2016010322A (es) 2017-04-27
EP3406609A1 (en) 2018-11-28
EP3102568A1 (en) 2016-12-14
CA2938169C (en) 2022-03-15
US10385039B2 (en) 2019-08-20
CY1120834T1 (el) 2019-12-11
HRP20241145T1 (hr) 2024-11-22
SG11201606269WA (en) 2016-09-29
RS65894B1 (sr) 2024-09-30
US10196380B2 (en) 2019-02-05
LT3406609T (lt) 2024-09-25
PT3102568T (pt) 2018-10-24
HK1231473A1 (en) 2017-12-22
RU2685230C2 (ru) 2019-04-17
JP2023087046A (ja) 2023-06-22
JP6774513B2 (ja) 2020-10-28
IL247117B (en) 2021-03-25
FI3406609T3 (fi) 2024-09-10
AU2019201579B2 (en) 2020-08-27
KR20160129014A (ko) 2016-11-08
PT3406609T (pt) 2024-09-17
CN106458986B (zh) 2019-01-04
JP2017505323A (ja) 2017-02-16
RS57843B1 (sr) 2018-12-31
SMT202400446T1 (it) 2024-11-15
US20190337925A1 (en) 2019-11-07
NZ723103A (en) 2022-09-30
BR112016017979B1 (pt) 2022-08-02
US20170015650A1 (en) 2017-01-19
MX393637B (es) 2025-03-11
RU2016133684A (ru) 2018-03-14
UA122121C2 (uk) 2020-09-25
PH12016501570A1 (en) 2016-10-03
US10689368B2 (en) 2020-06-23
JP2021006571A (ja) 2021-01-21
ES2688548T3 (es) 2018-11-05
SI3406609T1 (sl) 2024-10-30
LT3102568T (lt) 2018-11-12
US9926297B2 (en) 2018-03-27
CN109851610B (zh) 2021-09-21
JP7652832B2 (ja) 2025-03-27
US20170240530A1 (en) 2017-08-24
EP4413985A3 (en) 2024-10-23
CN109851610A (zh) 2019-06-07
IL247117A0 (en) 2016-09-29
PH12016501570B1 (en) 2016-10-03
AU2019201579A1 (en) 2019-03-28
SI3102568T1 (sl) 2018-11-30
EP3102568B1 (en) 2018-06-27
RU2016133684A3 (da) 2018-08-31
CN106458986A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
DK3406609T3 (da) Bicykliske aza-forbindelser som muskariniske receptoragonister
SG11201607458QA (en) Muscarinic receptor agonists
DK3125893T3 (da) Deutererede heterocyklus-fusionerede gamma-carboliner som antagonister af 5-ht2a-receptorer
IL250883A0 (en) Therapeutic compounds as orexin-1 receptor inhibitors
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
EP3365061A4 (en) AMINOISOXAZOLIN COMPOUNDS AS AGONISTS OF ALPHA7 NICOTINE ACETYLCHOLIN RECEPTORS
ZA201701210B (en) Substituted bicyclic compounds
IL256226A (en) Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
DK3277690T3 (da) Spirocykliske forbindelser
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
DK3792251T3 (da) Hidtil ukendte sulfonylaminobenzamidforbindelser som anthelmintika
ES2697898T8 (es) Compuestos triazólicos tricíclicos
GB201502644D0 (en) Bicyclic aza compounds as muscarinic m1 receptor agonists
TH1601003290A (th) สารประกอบไบไซคลิกเฮเทอโรไซเคิล
TH1601002112A (th) สารประกอบไบไซคลิกที่มีซัลเฟอร์
TH1601001484A (th) สูตรผสมสำหรับ cgrp รีเซปเตอร์แอนตะกอนิสต์
TH1601003792A (th) สารผสมสำหรับซักล้างชนิดผง
TH1601003483A (th) สารประกอบอินดาโซลในฐานะอะกอนิสต์ของ 5-ht4 รีเซปเตอร์